Register
A new triplet therapy for revlimid-refractory multiple myeloma |
Journal Updates
eMediNexus Coverage from: 
A new triplet therapy for revlimid-refractory multiple myeloma
eMediNexus,  09 November 2018
remove_red_eye 531 Views
#Oncology

0 Read Comments                

Based on the ELOQUENT-3 trial, the FDA has approved elotuzumab (Empliciti) in combination with pomalidomide (Pomalyst) and dexamethasone for the treatment of relapsed or refractory multiple myeloma. The trial showed that elotuzumab-treated patients had progression-free survival of 10.3 months compared with 4.7 months for those in the control group of pomalidomide and dexamethasone alone.

To continue reading this article
Or

Continue reading your article with a Emedinexus account..
Free Membership!